Ongoing Clinical Trials for Chronic Graft Versus Host Disease In Skin
This article presents information about 2 ongoing clinical trials investigating treatments for Chronic Graft Versus Host Disease In Skin. These studies are being conducted in several European countries and focus on different therapeutic approaches to managing this condition and related complications.
Clinical trial locations
- Germany
- Italy
- Netherlands
- Poland
- Sweden
Comparison of Tacrolimus alone versus Tacrolimus, Mycophenolate mofetil and Prednisone combination in elderly kidney transplant patients to reduce infections
This study is designed for elderly patients who have received a kidney transplant and focuses on finding the best medication approach to prevent infections. Researchers are comparing two different treatment strategies: using tacrolimus alone versus combining three medications (tacrolimus, mycophenolate mofetil, and prednisone).
Who can participate: Patients must be 60 years of age or older and receiving either a deceased donor or living donor kidney transplant. They must not have donor-specific anti-HLA antibodies at the time of transplantation. Previous kidney transplant recipients can participate if they meet all other criteria. Both men and women can take part in the study, and patients must be able to understand and sign a written informed consent document.
Who cannot participate: The study excludes patients with active or chronic infections, those who are pregnant or breastfeeding, and anyone with known allergies to immunosuppressive medications. Patients with severe heart, liver, or lung disease are not eligible, nor are those with active cancer or a history of cancer in the past 5 years. Other exclusion factors include uncontrolled diabetes, mental conditions that could affect the ability to follow study procedures, participation in other clinical trials within the past 30 days, history of substance abuse within the past 2 years, and inability to provide informed consent.
Main goal: The study aims to determine whether using a single medication approach with tacrolimus alone can reduce the risk of infections and improve quality of life compared to the standard three-drug combination. Researchers will monitor participants for three years after their kidney transplant, tracking the occurrence of infections, kidney function, and overall patient well-being through regular medical tests.
Investigational treatments: The study investigates tacrolimus as a single-drug therapy approach. Tacrolimus is an immunosuppressive medication that helps prevent organ rejection after kidney transplantation by weakening the immune system’s response to the transplanted kidney. The study compares this approach to the standard triple immunosuppressive therapy, which combines three different medications typically used after kidney transplantation to prevent organ rejection.
Study on Long-Term Safety of Ruxolitinib, Panobinostat, and Siremadlin for Patients Continuing Treatment from Previous Studies
This clinical trial focuses on evaluating the long-term safety of treatments for patients who have previously participated in studies involving ruxolitinib, either alone or in combination with other medications. Participants will continue their treatment as they have been doing in their previous studies while researchers monitor the frequency and severity of any side effects.
Who can participate: Patients must be currently enrolled in a study sponsored by Novartis or Incyte and receiving treatment with ruxolitinib alone or in combination with other medicines like panobinostat, siremadlin, or rineterkib. They must have met all the requirements of the original study they are part of and must be benefiting from the treatment they are receiving, as determined by the investigator. The study accepts both male and female patients from different age groups, including children, teenagers, and adults.
Who cannot participate: The study excludes patients who are not within the specified age range, those who do not meet the specific disease criteria outlined in the parent protocol, and patients who are not part of the clinical trial group specified for this study.
Main goal: The purpose of the study is to gather information on the long-term safety of ruxolitinib and its combinations over an extended period. The study will monitor any adverse events that occur during treatment and assess the clinical benefits patients experience from continued treatment. This open-label study is conducted at multiple centers, allowing for a diverse group of participants, and aims to provide valuable data that can benefit future patients who may receive these medications.
Investigational treatments: The study involves several medications. Ruxolitinib is typically used to treat certain types of blood disorders by helping to reduce symptoms. It works by inhibiting Janus kinase enzymes, which play a role in controlling blood cell production. Panobinostat is often used in combination with other treatments to help manage certain types of cancer by slowing down or stopping the growth of cancer cells through its action as a histone deacetylase inhibitor. Siremadlin is being studied for its potential to treat cancer by targeting specific pathways that cancer cells use to grow and survive, specifically by inhibiting the MDM2 protein. Rineterkib is being investigated for its ability to treat cancer by interfering with the processes that allow cancer cells to multiply and spread as a kinase inhibitor.
Summary
Two clinical trials are currently ongoing for patients affected by conditions related to transplantation and blood disorders. These studies are being conducted across several European countries, with one trial taking place in the Netherlands and another spanning multiple countries including Sweden, Poland, Germany, and Italy.
The first trial focuses specifically on elderly kidney transplant recipients and explores whether simplifying medication regimens can reduce infection risks while maintaining adequate organ protection. The second trial concentrates on long-term safety monitoring for patients who are already benefiting from treatment with ruxolitinib and related medications, providing valuable data on extended use of these therapies.
Both studies reflect important areas of ongoing research: optimizing treatment strategies for vulnerable patient populations and ensuring the long-term safety of newer therapeutic approaches. Patients interested in participating should discuss eligibility criteria with their healthcare providers to determine if these trials might be appropriate for their individual circumstances.
